metformin has been researched along with Shock, Cardiogenic in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Shock, Cardiogenic: Shock resulting from diminution of cardiac output in heart disease.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, W | 1 |
| Mehnert-Aner, S | 1 |
| Mülly, K | 1 |
| Heierli, C | 1 |
| Ritz, R | 1 |
1 other study available for metformin and Shock, Cardiogenic
| Article | Year |
|---|---|
[10 cases of lactic acidosis during biguanide therapy (buformin and phenformin)].
Topics: Acidosis; Biguanides; Buformin; Diabetes Mellitus; Glucagon; Humans; Lactates; Liver; Metformin; Phe | 1976 |